Exploratory biomarker findings from regorafenib plus toripalimab in patients with refractory metastatic colorectal cancer (REGOTORI study)
In this combination-therapy-focused multi-omics analysis integrating tissue genomics, ctDNA features/dynamics and TME profiling, we identified ctDNA maxAF, HAF-bTMB, bITH, HAF-bITH, mutational status of <i>SMAD4</i> or <i>PIK3CA</i> and TME markers as predictive or prognostic biomarkers for regorafenib plus toripalimab in refractory mCRC.
Authors
- Yongxin Mo
- Yan‐Xing Chen
- Yi-Chen Yao
- Ming-Ming He
- Qi Zhao
- Ting Hou
- Min Wang
- Feng Wang
- Ying Jin
Institutions
- Sun Yat-sen University (CN)
- Burning Rock Biotech (China) (CN)
- Cancer Hospital of Chinese Academy of Medical Sciences (CN)
- Sun Yat-sen University Cancer Center (CN)
Publication Details
- Journal
- Gastroenterology report
- Published
- 2026-01-20
- DOI
- https://doi.org/10.1093/gastro/goag009
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00